← Back

Scancell Hldgs Plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Price · split & dividend adjusted
News & notes moving SCLP.LSE
SCLP.LSE

Halper Sadeh LLC Investigates Whether SAFT, NEUP, RMAX, NRIM Are Obtaining Fair Deals for Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws or breaches of fiduciary duties to shareholders. The investigations concern Safety Insurance Group Inc.'s sale to an affiliate of Mapfre S.A. for $105.00 per share in cash, Neuphoria Therapeutics Inc.'s merger with Scancell Holdings plc where Neuphoria shareholders would own 14.5% of the combined company, RE/MAX Holdings Inc.'s sale to The Real Brokerage Inc. for either 5.152 shares of the combined company or $13.80 in cash per share, and Northrim BanCorp Inc.'s merger with PBCO Financial Corporation. The firm notes that insiders may receive substantial financial benefits not available to ordinary shareholders and that the proposed transactions may contain terms limiting superior competing offers. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
NEUP ▼NRIM ▼RMAX ▼SAFT ▼0NQ2.LSE SCLP.LSE
GlobeNewswire·27dRead more ▾
SCLP.LSE

Monteverde Law Firm Investigates Mergers of Northrim Bancorp, Neuphoria Therapeutics, Safety Insurance, and RE/MAX

Class action attorney Juan Monteverde of Monteverde & Associates PC announced investigations into four proposed mergers. The firm is examining Northrim Bancorp's merger with PBCO Financial Corporation, Neuphoria Therapeutics' merger with Scancell Holdings where Neuphoria stockholders would own 11.1% of the combined company, Safety Insurance Group's sale to a Mapfre affiliate at $105.00 per share in cash, and RE/MAX Holdings' sale to The Real Brokerage where shareholders may receive 5.152 shares of the combined company or $13.80 in cash per share. The RE/MAX shareholder vote is scheduled for August 14, 2026. Monteverde & Associates PC, a national class action securities firm headquartered at the Empire State Building, has recovered millions of dollars for shareholders and was recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
NEUP NRIM RMAX SAFT SCLP.LSE
GlobeNewswire·27dRead more ▾
Digital Finance & Tokenization▲

Zephyr Energy secures up to $15 million non-dilutive financing for Paradox Basin project

Zephyr Energy has lined up non-dilutive financing of up to $15 million for its Paradox Basin project in Utah, with Atlas Oil Company set to be repaid purely from future production, and no shares will be issued or working interest sold. Quantum Blockchain Technologies received US approval for a patent application covering technology to cut redundant calculations in Bitcoin mining hardware and will explore licensing deals with established ASIC manufacturers. Pathos Communications expects first-half revenue to jump 14% to $7.3 million and adjusted EBITDA to rise 31%, as its AI platform and new sales structure drive a roughly 30% increase in monthly client sign-ups and more than double repeat customers. AOTI reported underlying first-half revenue growth of 18%, ahead of full-year guidance, with Veterans Administration demand bouncing back strongly, and said proposed nationwide Medicare coverage for its wound-care technology could be transformative once finalized. Scancell Holdings confirmed its UK fundraise raised £15.7 million, with the retail offer upsized after strong demand, and the money will help fund a global phase III trial of its melanoma treatment alongside its merger with US biotech Neuphoria.
AOTI.LSE ▲NEWS.LSE ▲QBT.LSE ▲SCLP.LSE ▲ZPHR.LSE ▲
Digital Finance & Tokenization
Proactive Investors·31dRead more ▾
SCLP.LSE▲

Neuphoria confirms talks with Scancell about potential acquisition

Neuphoria Therapeutics confirmed it is in discussions with London-listed Scancell Holdings about a potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company after any deal. The statement follows an earlier announcement by Scancell about a possible combination, made after UK press speculation and in compliance with UK regulations. Neuphoria cautioned that there is no certainty an agreement will be reached, nor on the terms or whether a transaction will proceed. Any further announcements will be made in line with SEC and Nasdaq rules.
NEUP ▲SCLP.LSE ▲
GlobeNewswire·61dRead more ▾
© 2026 MarketDXAsset